IL258854B2 - Preparations containing cannabidiol and secondary pharmacological agents for cancer treatment - Google Patents

Preparations containing cannabidiol and secondary pharmacological agents for cancer treatment

Info

Publication number
IL258854B2
IL258854B2 IL258854A IL25885418A IL258854B2 IL 258854 B2 IL258854 B2 IL 258854B2 IL 258854 A IL258854 A IL 258854A IL 25885418 A IL25885418 A IL 25885418A IL 258854 B2 IL258854 B2 IL 258854B2
Authority
IL
Israel
Prior art keywords
cancer
cbd
cheh
aebs
cannabidiol
Prior art date
Application number
IL258854A
Other languages
English (en)
Hebrew (he)
Other versions
IL258854A (en
IL258854B1 (en
Original Assignee
Jay Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jay Pharma Inc filed Critical Jay Pharma Inc
Publication of IL258854A publication Critical patent/IL258854A/en
Publication of IL258854B1 publication Critical patent/IL258854B1/en
Publication of IL258854B2 publication Critical patent/IL258854B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL258854A 2015-10-27 2016-10-27 Preparations containing cannabidiol and secondary pharmacological agents for cancer treatment IL258854B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562246780P 2015-10-27 2015-10-27
PCT/IL2016/051166 WO2017072773A1 (en) 2015-10-27 2016-10-27 Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer

Publications (3)

Publication Number Publication Date
IL258854A IL258854A (en) 2018-06-28
IL258854B1 IL258854B1 (en) 2025-02-01
IL258854B2 true IL258854B2 (en) 2025-06-01

Family

ID=57406292

Family Applications (1)

Application Number Title Priority Date Filing Date
IL258854A IL258854B2 (en) 2015-10-27 2016-10-27 Preparations containing cannabidiol and secondary pharmacological agents for cancer treatment

Country Status (10)

Country Link
US (1) US11090275B2 (enExample)
EP (1) EP3368024B1 (enExample)
JP (1) JP7078538B2 (enExample)
KR (1) KR20180102053A (enExample)
CN (1) CN109310648B (enExample)
AU (1) AU2016347662B2 (enExample)
BR (1) BR112018008601A2 (enExample)
CA (2) CA3187317A1 (enExample)
IL (1) IL258854B2 (enExample)
WO (1) WO2017072773A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020161083A1 (en) * 2019-02-04 2020-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
MX2022000027A (es) * 2019-07-02 2022-04-11 Ellevet Sciences Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales.
EP3826630B1 (en) * 2019-07-21 2022-06-29 SCF Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides and use thereof
WO2021203206A1 (en) * 2020-04-09 2021-10-14 Laviolette Steven Robert Combination of cannabidiol and a ppar agonist
CN111773390B (zh) * 2020-07-01 2021-08-20 南京大学 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用
CN113368085A (zh) * 2021-06-05 2021-09-10 昆明医科大学第一附属医院 大麻二酚在调节肿瘤微生态治疗乳腺癌药物研制中的应用
CN113384563A (zh) * 2021-06-16 2021-09-14 冯敏 大麻二酚在制备治疗非霍奇金淋巴瘤的药物中的应用
KR20240116462A (ko) 2021-10-26 2024-07-29 더 유니버시티 오브 뉴캐슬 대마 추출물로 난소암을 치료하는 방법
CA3235077A1 (en) 2021-10-26 2023-05-04 Alex Nance Systems and methods for producing hemp extracts and compositions
AU2022379618A1 (en) 2021-10-26 2024-05-23 Dove Innovation Pty Limited Methods of treating endometriosis and other non-cancer gynecological disorders with hemp extract
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
EP4548102A1 (en) * 2022-06-30 2025-05-07 Univerza v Mariboru Cannabinoid compositions against cancer, their identification and personalization of cannabis-based cancer therapy
US20240009211A1 (en) * 2022-07-05 2024-01-11 Neocannbio Co., Ltd. Pharmaceutical composition for treatment of lung cancer comprising cannabidiol and anticancer agent as active ingredients, and use thereof
KR20240036953A (ko) * 2022-09-14 2024-03-21 주식회사 네오켄바이오 칸나비디올 및 항암제를 유효성분으로 포함하는 간암 치료용 약학 조성물 및 이의 용도
US12097211B2 (en) 2022-10-26 2024-09-24 Ecofibre USA Inc. Methods of treating estrogen sensitive diseases with cannabis extract
US12011451B2 (en) 2022-10-26 2024-06-18 Ecofibre USA Inc. Stabilized compositions comprising cannabidiol
WO2024097631A2 (en) * 2022-11-02 2024-05-10 Morehouse School Of Medicine Methods of treating pain and drepression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2460672A (en) * 2008-06-04 2009-12-09 Gw Pharma Ltd Cancer medication using cannabinoids in combination with non-cannabinoids

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
AU664978B2 (en) * 1990-12-17 1995-12-14 University Of Manitoba Improved treatment method for cancer
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
US20020040011A1 (en) * 2000-06-01 2002-04-04 Brown Dennis M. Naphthoquinone compositions and uses thereof
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US9084771B2 (en) * 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
FR2947340B1 (fr) * 2009-06-25 2011-08-12 Affichem Detection de l'etat oncogene de cellules humaines ou de mammiferes par presence d'un marqueur et evaluation de l'activite d'un medicament par dosage dudit marqueur
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
GB2515312A (en) * 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2460672A (en) * 2008-06-04 2009-12-09 Gw Pharma Ltd Cancer medication using cannabinoids in combination with non-cannabinoids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OZTOPCU-VATAN, P., ET AL.:, CYTOTOXIC AND APOPTOTIC EFFECTS OF MENADIONE ON RAT HEPATOCELLULAR CARCINOMA CELLS, 15 May 2014 (2014-05-15) *
SILVENTE-POIROT, S. AND MARC POIROT., CHOLESTEROL EPOXIDE HYDROLASE AND CANCER., 21 August 2012 (2012-08-21) *

Also Published As

Publication number Publication date
AU2016347662A1 (en) 2018-05-10
EP3368024B1 (en) 2023-09-20
US11090275B2 (en) 2021-08-17
IL258854A (en) 2018-06-28
JP2018536706A (ja) 2018-12-13
IL258854B1 (en) 2025-02-01
CA3002767C (en) 2023-03-14
CA3187317A1 (en) 2017-05-04
JP7078538B2 (ja) 2022-05-31
CN109310648B (zh) 2022-06-03
BR112018008601A2 (pt) 2018-10-30
CA3002767A1 (en) 2017-05-04
US20180311182A1 (en) 2018-11-01
KR20180102053A (ko) 2018-09-14
WO2017072773A1 (en) 2017-05-04
EP3368024A1 (en) 2018-09-05
CN109310648A (zh) 2019-02-05
AU2016347662B2 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
IL258854B2 (en) Preparations containing cannabidiol and secondary pharmacological agents for cancer treatment
Davis et al. Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension
US20220054429A1 (en) Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
Hu et al. Salidroside induces cell-cycle arrest and apoptosis in human breast cancer cells
Ciechomska et al. Endoplasmic reticulum stress triggers autophagy in malignant glioma cells undergoing cyclosporine a-induced cell death
Kang et al. Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways
US10098867B2 (en) Use of phytocannabinoids in the treatment of ovarian carcinoma
Pawlik et al. Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants
Si et al. Silibinin-induced mitochondria fission leads to mitophagy, which attenuates silibinin-induced apoptosis in MCF-7 and MDA-MB-231 cells
JP5620443B2 (ja) 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ
Biteghe et al. A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells
Zhou et al. Eriocalyxin B, a novel autophagy inducer, exerts anti-tumor activity through the suppression of Akt/mTOR/p70S6K signaling pathway in breast cancer
Xu et al. Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2/M cell cycle arrest, apoptosis, and autophagy
Liu et al. Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells
Campos et al. GDNF contributes to oestrogen‐mediated protection of midbrain dopaminergic neurones
Yu et al. Antiestrogenic effect of 20S‐protopanaxadiol and its synergy with tamoxifen on breast cancer cells
Dewangan et al. Chetomin induces apoptosis in human triple-negative breast cancer cells by promoting calcium overload and mitochondrial dysfunction
WO2023062634A1 (en) Compositions comprising cannabinoids and methods of use thereof in the treatment of cancer
Jumnongprakhon et al. Protective effect of melatonin on methamphetamine-induced apoptosis in glioma cell line
Wang et al. Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy
Gaelzer et al. Phosphatidylinositol 3-kinase/AKT pathway inhibition by doxazosin promotes glioblastoma cells death, upregulation of p53 and triggers low neurotoxicity
Lin et al. PF-429242 exhibits anticancer activity in hepatocellular carcinoma cells via FOXO1-dependent autophagic cell death and IGFBP1-dependent anti-survival signaling
Da Fonseca et al. Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review
Yang et al. Ti3C2 nanosheet-induced autophagy derails ovarian functions
Sun et al. Insulin like growth factor-1 prevents 1-mentyl-4-phenylphyridinium-induced apoptosis in PC12 cells through activation of glycogen synthase kinase-3beta